CSF1R and B-cell chronic lymphocytic leukemia: Moreover, many patient samples that had been resistant to ibrutinib and idelalisib alone became sensitive to the inhibitor in combination with GW-2580 or ARRY-382, suggesting the broad applicability of using CSF1R inhibitors with currently approved inhibitors to target CLL.